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Methylation of the N6 position of adenosine (m6A) is
a posttranscriptional modification of RNAwith poorly
understood prevalence and physiological relevance.
The recent discovery that FTO, an obesity risk gene,
encodes an m6A demethylase implicates m6A as an
important regulator of physiological processes.
Here, we present a method for transcriptome-wide
m6A localization, which combines m6A-specific
methylated RNA immunoprecipitation with next-
generation sequencing (MeRIP-Seq). We use this
method to identify mRNAs of 7,676 mammalian
genes that contain m6A, indicating that m6A is
a common base modification of mRNA. The m6A
modification exhibits tissue-specific regulation and
is markedly increased throughout brain develop-
ment. We find that m6A sites are enriched near stop
codons and in 30 UTRs, and we uncover an associa-
tion between m6A residues and microRNA-binding
sites within 30 UTRs. These findings provide
a resource for identifying transcripts that are
substrates for adenosine methylation and reveal
insights into the epigenetic regulation of themamma-
lian transcriptome.INTRODUCTION
The fat mass and obesity-associated (FTO) gene is a major regu-
lator of metabolism and energy utilization (Church et al., 2009,
2010; Fischer et al., 2009). In humans, FTO polymorphisms
that increase FTO expression are associated with elevated
body mass index and increased risk for obesity (reviewed in
Fawcett and Barroso, 2010). FTO is a member of the Fe(II)-
and oxoglutarate-dependent AlkB oxygenase family and was
originally shown to catalyze the oxidative demethylation of meth-
ylated thymidine and uracil (Gerken et al., 2007; Jia et al., 2008).
However, FTO exhibits low activity toward these base modifica-tions, and they are relatively infrequent with unclear physiolog-
ical relevance (Klagsbrun, 1973). Thus, the physiologically
relevant targets of FTO were unclear until recent studies that
showed that FTO can demethylate N6-methyladenosine (m6A),
a naturally occurring adenosine modification (Jia et al., 2011).
These studies link adenosine methylation to physiological roles
in human biological processes.
The distribution of m6A in RNA is poorly understood. Previous
studies have found that m6A exists in RNA from a variety of
unique organisms, including viruses, yeast, and mammals (Bee-
mon and Keith, 1977; Bodi et al., 2010). m6A is found in tRNA
(Saneyoshi et al., 1969), rRNA (Iwanami and Brown, 1968), and
viral RNA (Beemon and Keith, 1977; Dimock and Stoltzfus,
1977). Although m6A is detectable in mRNA-enriched RNA frac-
tions (Desrosiers et al., 1974), it has been confirmed in vivo in
only one mammalian mRNA (Horowitz et al., 1984). The abun-
dance of m6A has been shown to be 0.1%–0.4% of total adeno-
sine residues in cellular RNA (Dubin and Taylor, 1975; Perry et al.,
1975; Wei et al., 1975), suggesting that this modification may
be widespread throughout the transcriptome. Although the
existence of m6A has been known for many years, progress in
establishing the prevalence of m6A in mRNA has lagged behind
that of other modified bases. This is due in large part to the lack
of available methods for detecting the presence of m6A.
Because methylation of adenosine does not alter its ability to
base pair with thymidine or uracil, m6A is not amenable to detec-
tion with standard hybridization or sequencing-based methods.
Here, we examine the prevalence, regulation, and functional
roles of m6A in the transcriptome. We show that m6A is a devel-
opmentally regulated RNA modification that is dynamically
modified. Using antibodies that recognize m6A, we have devel-
oped an affinity enrichment strategy that, when coupled with
next-generation sequencing, allows for the high-throughput
identification of m6A sites. Using this approach, we present the
first transcriptome-wide profile of m6A localization in RNA. We
find that m6A is a widespread modification that is present in
the mRNAs of >7,600 genes and in >300 noncoding RNAs.
Additionally, m6A is highly enriched near the stop codon and in
the 30 UTR. Furthermore, bioinformatic analysis of m6A localiza-
tion reveals consensus sites for m6A and identifies a potential
interaction between m6A and microRNA pathways.Cell 149, 1635–1646, June 22, 2012 ª2012 Elsevier Inc. 1635
Figure 1. Specificity and Sensitivity of m6A-
Specific Antibody
(A) Dot blot analysis demonstrates antibody specificity for
m6A. Increasing amounts of an oligonucleotide containing
either m6A or unmodified adenosine were spotted onto
a membrane and probed with the m6A antibody. Though
increased m6A immunoreactivity is observed in the pres-
ence of increasing concentrations of the m6A oligonucle-
otide (top), only background levels of immunoreactivity are
observed at the highest concentrations of the A oligonu-
cleotide (bottom). Blots shown are representative of
results from three experiments.
(B) Competition dot blot assays were performed on
membranes spotted with 100 ng of m6A-containing
oligonucleotide. Antibody binding to the m6A oligonucle-
otide is attenuated by preincubation with increasing
amounts of m6A-containing competitor RNA (top), but not
with RNA containing unmodified adenosine (bottom).
Amount of competitor RNA used (left to right): 0 ng (0 nM),
10 ng (0.1 nM), 100 ng (1.1 nM), 1 mg (11.2 nM). Blots
shown are representative of results from four experiments.
(C) Competition dot blot assays were performed as in (B).
Antibody was preincubated with increasing amounts
of N6-methyladenosine triphosphate (N6-MeATP), aden-
osine triphosphate (ATP), N1-methyladenosine triphos-
phate (N1-MeATP), or 20-O-methyladenosine triphosphate
(20-O-MeATP). Only N6-MeATP is able to compete with
antibody binding. Concentration of competitor nucleotide
used (left to right): 0 mM, 1 mM, 2 mM, 4 mM. Blots shown are representative of results from three experiments.
(D) Detection of m6A in cellular DNA. Genomic DNA isolated from dam+ (containing m6A) or dam (lacking m6A) E. coli was sheared and subjected to
immunoblotting with the m6A antibody. Although 1.5 times as much DNA from dam E. coli was loaded (left), the antibody only recognizes the m6A present in
DNA from dam+ E. coli (right). Blot shown is representative of results from three experiments.
See also Figure S2.RESULTS
Detection of m6A in Mammalian mRNA
Because m6A exhibits the same base pairing as unmodified
adenosine, it is not readily detectable by standard sequencing
or hybridization-based approaches. Additionally, m6A is not
susceptible to chemical modifications that might otherwise facil-
itate its detection, such as bisulfite treatment, which is used to
detect 5mC in DNA. The methods used thus far to detect m6A
have involved treating cells with radiolabeled methionine, the
precursor of the endogenous methylating agent S-adenosylme-
thionine, to impart radiolabeled methyl groups to adenosine
(Csepany et al., 1990; Dubin and Taylor, 1975; Narayan and
Rottman, 1988). Radiolabeled m6A residues are subsequently
mapped with thin-layer chromatography or HPLC.
In order to simplify detection of m6A, we sought to develop an
immunoblotting strategy. For these experiments, we used
a previously described anti-m6A antibody (Bringmann and Lu¨hr-
mann, 1987; Jia et al., 2011; Munns et al., 1977). To ensure the
specificity of this antibody for m6A, we performed dot blots using
modified oligonucleotides immobilized to a membrane. The m6A
antibody selectively bound to oligonucleotides containing a
single m6A residue and exhibited negligible binding to oligonu-
cleotides containing unmodified adenosine (Figure 1A). The
binding was competed by incubating the antibody with
increasing concentrations of an m6A-rich competitor RNA (Fig-
ure 1B). However, RNA containing unmodified adenosine did
not compete for binding. Furthermore, binding was competed1636 Cell 149, 1635–1646, June 22, 2012 ª2012 Elsevier Inc.by N6-methyladenosine triphosphate, but not by ATP or other
modified adenosine triphosphates, including N1-methyladeno-
sine and 20-O-methyladenosine (Figure 1C). Finally, to examine
the specificity of the antibody in the context of other nucleotide
sequences, we took advantage of the fact that the enzyme
encoded by the DNA adenine methylase (dam) gene in E. coli
methylates theN6 position of adenosine in DNA. Upon subjecting
digested DNA isolated from dam+ and dam- E. coli to immuno-
blotting using the m6A antibody, we found robust signals only in
the DNA samples from the dam+ strain (Figure 1D). Collectively,
these data demonstrate the high sensitivity and selectivity of this
antibody for m6A, as well as its ability to detect m6A within
cellular nucleotide pools.
To explore the abundance of m6A within various RNA
populations, we isolated RNA from several mouse tissues and
subjected it to immunoblot analysis using the m6A antibody (Fig-
ure 2A). We found that m6A was present in all RNA samples
tested, indicating that this modified nucleotide is widely distrib-
uted in many tissues, with particularly high enrichment in liver,
kidney, and brain (Figure 2B). In addition, we observed large
differences in the m6A content of various immortalized cell lines,
including several cancer cell lines, which further indicates that
large differences in m6A levels exist in different cell populations
(Figure S1A available online).
m6A immunoreactivity was detected in bands throughout the
molecularweight range of the blot (0.2 kb to10 kb), consistent
with incorporation of m6A in mRNA. Indeed, fractionation of
whole cellular RNA into polyadenylated and nonpolyadenylated
Figure 2. Distribution and Dynamic Cellular Regu-
lation of m6A in RNA
(A) Widespread distribution of m6A levels in a variety of
tissues. Total RNA isolated from mouse brain, heart, lung,
liver, and kidney (top) was subjected to m6A immunoblot
analysis. Ethidium bromide staining of the 28S rRNA is
shown as a loading control (bottom).
(B) Quantification of m6A abundance within various
tissues. Quantification of m6A immunoreactivity in (A) was
measured by densitometry and normalized to the intensity
of the corresponding 28S rRNA band for each tissue (n = 3;
data are presented as mean ± SEM).
(C) m6A is enriched within mRNAs. Oligo(dT) Dynabeads
were used to isolate poly(A) RNA from total mouse brain
RNA, and the unbound ‘‘flowthrough’’ RNA was saved as
the poly(A)-depleted fraction. Equal amounts of total RNA,
poly(A) RNA, and poly(A)-depleted RNA were then
subjected to m6A immunoblot analysis (top). Ethidium
bromide staining of 28S rRNA is shown as a loading
control (bottom). Intense m6A immunoreactivity is
observed in the poly(A) RNA fraction, consistent with high
levels of m6A within mRNAs.
(D) Depletion of poly(A) tails from mRNA does not reduce
levels of m6A in mRNA. Poly(A) RNA was isolated from
total mouse brain RNA using oligo(dT) Dynabeads. Half
of the sample was then subjected to poly(A) tail depletion
by hybridizing to oligo(dT) primers and digestion with
RNase H. Immunoblot analysis with them6A antibody (top)
shows that levels of m6A in poly(A) RNA (left) and poly(A)
tail-depleted RNA (right) are comparable. Removal of
poly(A) tails was confirmed using 30RACE and RT-PCR to detect b-actin; no product is detected in the tail-depleted sample when oligo(dT) primers are used for
cDNA synthesis (middle). As a control, use of random hexamers successfully generates a product in both samples (bottom).
See also Figure S1.RNAs indicates that m6A immunoreactivity is enriched in the pol-
yadenylated RNA pool, which further suggests that m6A in
cellular RNA is localized to mature mRNA (Figure 2C). To deter-
mine whether m6A is present in poly(A) tails, we selectively
removed the poly(A) tail from cellular mRNA using oligo(dT)
hybridization and RNase H treatment. Transcripts depleted of
the poly(A) tail did not exhibit an appreciable reduction in m6A
levels (Figure 2D). In addition, immunoblotting poly(A) tails alone
showed minimal m6A immunoreactivity (Figures S2C–S2E).
Together, these data demonstrate that m6A is primarily an
internal modification that is largely absent from the poly(A) tail.
Dynamic Regulation of m6A
Our observation that m6A is highly enriched within the brain
prompted us to investigate the temporal dynamics of m6A levels
during different stages of neural development. Immunoblotting
RNAsampleswith them6Aantibody indicates thatm6A is present
in mRNA at low levels throughout embryogenesis but increases
dramatically by adulthood (Figure 3A). A similar increase in m6A
levels is also observed in RNA isolated from embryonic and post-
natal rat brain cultured neurons (Figure S1B), which suggests that
upregulation of m6A levels accompanies neuronal maturation.
We next asked whether adenosine methylation is a dynami-
cally regulated posttranscriptional modification and whether its
levels can be regulated by specific demethylating enzymes. In
our search for potential demethylating enzymes that act to re-
move the methyl group from m6A, we focused on members of
the family of Fe(II)- and 2-oxoglutarate-dependent oxygenases,several of which have previously been shown to demethylate
both DNA and RNA (Falnes et al., 2007; Gerken et al., 2007).
Consistent with the findings of Jia et al. (2011), we observed
that FTO decreasedm6A levels when overexpressed in mamma-
lian cells (Figure 3B). Furthermore, we find that overexpression of
FTO resulted in a broad size range of RNAs that exhibit reduced
m6A immunoreactivity (Figure 3B).
MeRIP-Seq Identifies m6A-Containing RNAs throughout
the Transcriptome
In order to obtain insight into potential roles for m6A, we sought
to characterize its distribution throughout the transcriptome. To
do this, we first determined whether the m6A antibody could be
used to enrich m6A-containing RNAs. In vitro immunoprecipita-
tion experiments showed that a single round of MeRIP produces
70-fold enrichment, and two rounds produce >130-fold enrich-
ment for m6A-containing targets (Figure S3). To identify m6A
sites throughout the transcriptome, we developed a method
that combines m6A-specific methylated RNA immunoprecipita-
tion (MeRIP) with next-generation sequencing (RNA-Seq). The
procedure for MeRIP-Seq (outlined in Figure 4A) involves
randomly fragmenting the RNA to 100 nt sized fragments prior
to immunoprecipitation. Because anm6A site could lie anywhere
along the length of a given immunoprecipitated 100 nt fragment,
sequencing reads are expected to map to a region that contains
the m6A site near its center. At its extremes, this region would be
predicted to be roughly 200 nt wide (100 nt up- and downstream
from the m6A site) (Figures 4B and 4C).Cell 149, 1635–1646, June 22, 2012 ª2012 Elsevier Inc. 1637
Figure 3. Regulation of m6A Levels in Cells and during Development
(A) Ontogeny of m6A abundance throughout brain development. Total RNA
was isolated frommouse brain at embryonic day 18 (E18), postnatal day 0 (P0),
postnatal day 14 (P14), and adulthood and was then subjected to immunoblot
analysis to detect m6A-containing transcripts. Ethidium bromide staining of
28S rRNA bands is shown as a loading control.
(B) FTO demethylates a wide range of cellular transcripts. FTO was expressed
in HEK293T cells for 48 hr, and cellular RNA was subjected to immunoblot
analysis to detect m6A.
See also Figure S1.We next utilized MeRIP-Seq to identify m6A sites in total
mouse brain RNA. Reads from the MeRIP sample frequently
mapped to mRNAs and clustered as distinct peaks. As pre-
dicted, these peaks frequently converged to 100 nt wide
regions near their midpoint (Figure 4C). Furthermore, enrichment
of reads in these regions was not observed in the non-IP control
sample, which was composed of the input RNA prior to m6A
immunoprecipitation, demonstrating the specificity of these
peaks (Figure S3).
To determine the location of these peaks throughout the
transcriptome and thus characterize the regions of m6A localiza-
tion, we developed an algorithm for identifying m6A peaks
(see Extended Experimental Procedures). Additionally, we per-
formed replicate MeRIP-Seq experiments in which we utilized:
(1) a different sequencing platform (Illumina’s GAIIx versus
HiSeq2000), (2) independently prepared RNA samples from
different animals, and (3) an unrelated m6A antibody (Kong
et al., 2000), which exhibited similarly high specificity for m6A
(Figure S4). We employed our algorithm to identify m6A peaks
that met a minimum p value (p% 0.05, Benjamini and Hochberg
corrected) within each individual sample. From the three
samples, we identified a total of 41,072 distinct peaks in the
RNAs of 8,843 genes, which we call our ‘‘filtered’’ set of m6A
peaks (Table S1). Of these peaks, 80% were detected in at least
two different replicates. The high concordance between these
samples indicates that MeRIP-Seq is highly reproducible across
different sequencing platforms and using different m6A anti-
bodies. For subsequent bioinformatic analyses, we used the
list of 13,471 m6A peaks in RNAs from 4,654 genes that were
detected in all three replicates (our ‘‘high-confidence’’ list; Table
S2A). This list demonstrates the presence of m6A in a substantial
fraction of the transcriptome and indicates thatm6A is a common
feature of mammalian mRNAs.
m6A Is Detected in Noncoding RNAs
The majority of our high-confidence m6A peaks (94.5%) are
found within mRNAs. However, we also observed that 2361638 Cell 149, 1635–1646, June 22, 2012 ª2012 Elsevier Inc.(1.8%) of our peaks mapped to noncoding RNAs (ncRNAs) that
were annotated in the RefSeq database (Table S2A). In addition,
588m6A peaks did notmap to a knownRefSeqmRNA or ncRNA.
To determine whether these unannotated peaks localize to
ncRNAs predicted in other databases, we aligned them to
genomic regions of a set of 32,211 ncRNAs from the RIKEN
functional annotation of mouse (FANTOM3) data set that we
obtained from the mammalian noncoding RNA database
(RNAdb; Pang et al., 2005). We found that 216 of these peaks
mapped to a FANTOM3 ncRNA (Table S2B). All of these ncRNAs
were >200 nt in length, indicating that long ncRNAs are
substrates for adenosine methylation. Additionally, when we
interrogated a set of conserved human lincRNAs (Cabili et al.,
2011) for overlaps with m6A peaks, we found nine additional
peaks that overlapped with these lincRNAs (Table S2C). Collec-
tively, these data identify several classes of ncRNAs as targets of
adenosine methylation.
Biochemical Validation of m6A-Containing Transcripts
We next sought to validate the presence of m6A in mRNAs
identified with MeRIP-Seq. To do this, we used RNA pull-down
assays to isolate individual mRNAs from total mouse brain
RNA by hybridization to target-specific probes. Isolated mRNAs
were then subjected to immunoblot analysis using the m6A
antibody to detect the presence of m6A. Using this method, we
validated the presence of m6A within low density lipoprotein
receptor (Ldlr) (Figures 5A and 5B), metabotropic glutamate
receptor 1 (Grm1), and dopamine receptor D1A (Drd1a) (Figures
S5A–S5D). These mRNAs were chosen to demonstrate our
ability to validate m6A presence in transcripts with multiple
methylation sites (Grm1 and Drd1a) as well as those with single
m6A peaks (Ldlr). To further demonstrate that MeRIP-Seq selec-
tively enriches for these endogenous methylated targets, we
performed qRT-PCR on the unbound fractions after RNA precip-
itation with the m6A antibody. As expected, we observed
substantial immunodepletion of Grm1, Drd1a, and other methyl-
ated targets in the unbound fraction. In contrast, transcripts that
lack m6A peaks, such as Rps21 and Ndel1, were detectable at
high levels in the unbound fraction (Figure S5E).
m6A-Containing mRNAs Are Involved in Important
Biological Pathways
To predict potential signaling pathways and cellular processes
that involve m6A, we used the DAVID bioinformatics database
to identify the gene ontology (GO) terms that are enriched for
m6A-containing transcripts. We found that genes encoding
m6A-containing RNAs are involved in a variety of cellular func-
tions, including transcriptional regulation, RNA metabolism,
and intracellular signaling cascades (Table S5). In addition,
we observed that m6A peaks mapped to many genes linked to
neurodevelopmental and neurological disorders, such as Bdnf,
Dscam, Lis1, and Ube3a, as well as the neurexins and several
neuroligins. Collectively, these data demonstrate that m6A-
containing RNAs are involved in a variety of biological pathways
that are relevant to cellular signaling and disease.
Because m6A is a physiological target of FTO, we sought
to determine whether mRNAs whose levels have previously
been shown to be influenced by FTO activity contain m6A. We
Figure 4. Outline of MeRIP-Seq Protocol
and Distribution of Sequencing Reads
(A) Schematic representation of MeRIP-Seq. Total
RNA is subjected to RiboMinus treatment to
remove rRNA species. RNAs containing m6A are
then immunoprecipitated by mixing the RNA with
m6A antibody-coupled Dynabeads. m6A-contain-
ing RNAs are then eluted from the antibody-
coupled beads and subjected to a second round
of m6A immunoprecipitation. The resulting RNA
pool, which is highly enriched for m6A-containing
RNAs, is then subjected to next-generation
sequencing.
(B) Schematic of sequencing reads and their
alignment to locations in the genome surrounding
an m6A site. (Top) An mRNA that contains a single
m6A residue along its length. (Middle) Individual
100 nt wide mRNA fragments that are isolated
following m6A immunoprecipitation, each of which
contains the same m6A residue from the mRNA
depicted above. (Bottom) Histogram showing
predicted frequency of MeRIP-Seq reads ob-
tained by sequencing individual immunoprecipi-
tated fragments. Read frequency is predicted to
increase with closer proximity to the m6A site,
forming a ‘‘peak’’ that is roughly 200 nt wide at its
base and 100 nt wide at its midpoint.
(C) Sequencing reads from MeRIP-Seq converge
overm6A sites. Representative UCSCGenomeBrowser plot fromMeRIP-Seq data, which demonstrates typical read frequency peak formation surrounding a site
of m6A (shown here is the 30 UTR of Pax6). Peak height is displayed as reads per base per million mapped reads (BPM).
See also Figures S2 and S3.examined a list of 77 mRNAs whose levels are either up- or
downregulated in the liver, skeletal muscle, or white adipose
tissue of mice homozygous for a nonsynonymous FTO point
mutation (Church et al., 2009). mRNAs from seven genes that
were significantly upregulated in FTO mutants (Acaca, Atf6,
Bip,Gcdh, Irs1, Perk, and Xbp1) also contain m6A peaks. Intrigu-
ingly, some of these genes are involved in important metabolic
pathways, raising the possibility that demethylation of the tran-
scripts of these genes may contribute to the mechanism by
which FTO regulates metabolism and energy homeostasis.
Diverse Patterns of m6A Localization within Transcripts
We next characterized the pattern of adenosine methylation in
mRNAs. mRNAs from many genes (46.0%) exhibit a single m6A
peak, consistent with a single m6A site or a cluster of adjacent
m6A residues. However, 37.3% contain two m6A peaks, 11.2%
contain three peaks, and 5.5% contain four or more peaks.
Several genescontain10ormorem6Apeaks, suggesting theexis-
tenceofmultiplem6A residuesalong their length. Indeed, of the 20
genes that exhibited the largest number of m6A peaks, all had 15
or more m6A peaks along their length (Table S3). Additionally, of
the genes that contain more than one m6A peak, 90.1% contain
two or more contiguous m6A peaks, suggesting that m6A sites
are frequently clustered in adjacent regions along the transcript.
Indeed, 32.8%ofm6Apeaks arepart of clusters that contain three
or more adjacent m6A peaks, suggesting that m6A clustering is
a common feature in methylated transcripts (Figure S6A). We
also identified68genes that have long (R1kb) stretchesof contig-
uousm6A peaks (Table S4), which likely indicates the presence of
multiple m6A residues throughout these regions.We next determined which mRNAs contain m6A sites with the
highest degree of methylation. To do this, we developed
a method of calculating the level of m6A enrichment at individual
m6A peaks, which normalized the number of MeRIP sample
reads within each peak to the abundance of the individual tran-
script in which the peak resides (see Extended Experimental
Procedures). The genes that contain the most enriched m6A
peaks are listed in Table 1. Importantly, because MeRIP-Seq
identifies m6A sites at a resolution of 200 nt, there could be
multiple individual m6A residues within the area covered by
each peak. Therefore, the peaks with the highest levels of local
m6A enrichment may represent a single adenosine residue that
exhibits a high degree of methylation or multiple adjacent m6A
residues with a lower stoichiometry of methylation. In either
case, the high levels of methylation observed at these sites likely
indicate transcripts that are most influenced by m6A-dependent
regulatory processes.
m6A Is Enriched near Stop Codons and in 30 UTRs
of mRNAs
Wenext examined the distribution ofm6A peakswithin regions of
the transcriptome in our high confidence set. The majority
(94.8%) ofm6A peaks occurwithin intragenic regions (Figure 5C).
These m6A peaks are abundant in coding sequences (CDS;
50.9%) and untranslated regions (UTRs; 41.9%), with relatively
few in intronic regions (2.0%) (Figure 5C). Additionally, m6A
peaks are less abundant in the 50 UTR (7.0% of UTR peaks)
than in the 30 UTR (93.0% of UTR peaks) (Figure 5C). This distri-
bution deviates substantially from the distribution of reads in
the non-IP sample, indicating the high degree of enrichment ofCell 149, 1635–1646, June 22, 2012 ª2012 Elsevier Inc. 1639
Figure 5. Validation of m6A Targets and Characteristics of m6A Localization
(A) Different sequencing platforms and antibodies result in similar m6A profiles. UCSC Genome Browser tracks displaying read clusters from three MeRIP-Seq
replicates (MeRIP1, MeRIP2, and MeRIP3) are shown along the length of the Ldlr transcript. The upper-most track (non-IP) represents the non-
immunoprecipitated control sample.
(B) Validation of m6A-containing mRNA identified with MeRIP-Seq. Hybridization-based RNA pull-down was used to isolate Ldlr mRNA from total brain RNA,
followed by confirmation of m6A presence (arrow) by immunoblot analysis with anti-m6A. A control sample using a nonspecific probe of equal size (CTL Probe)
was run in parallel. Total mouse brain RNA (Input) is shown as a reference for m6A labeling.
(C) Transcriptome-wide distribution of m6A peaks. Pie charts showing the percentage of m6A peaks (top) and non-IP sample reads (bottom) within distinct RNA
sequence types. m6A is highly enriched in 30 UTRs and CDSs compared to the distribution of reads in the non-IP, rRNA-depleted samples.
(D) Distribution of m6A peaks across the length of mRNA transcripts. 50 UTRs, CDSs, and 30 UTRs of RefSeq mRNAs were individually binned into regions
spanning 1% of their total length, and the percentage of m6A peaks that fall within each bin was determined. The moving averages of mouse brain peak
percentage (red) and HEK293T peak percentage (blue) are shown.
(E) Highly similar m6A peak distribution is observed within many human and mouse transcripts. UCSC Genome Browser plots showing MeRIP-Seq read clusters
in the representative transcript SREK1. MeRIP-Seq reads cluster at the same distinct regions of SREK1 in both HEK293T cell RNA (top) and mouse brain RNA
(bottom).
See also Figures S4–S7 and Tables S1–S6.
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Table 1. Genes Encoding Transcripts with the Highest Degree of m6A Enrichment
Chr Peak Start Peak End RefSeq Accession Gene Symbol Enrichment Score
chr6 58856032 58856214 NM_021432 Nap1l5 3.859
chr3 30717625 30717825 NM_027016 Sec62 3.693
chr3 88566067 88566234 NM_018804 Syt11 3.452
chr6 58855850 58856032 NM_021432 Nap1l5 3.327
chr19 5801367 5801534 NR_002847 Malat1 3.322
chr12 110898950 110899150 NR_028261 Rian 3.222
chr10 34018834 34018993 NM_030203 Tspyl4 3.162
chr17 6138575 6138775 NM_054040 Tulp4 2.984
chr2 34631357 34631514 NM_001163434 Hspa5 2.935
chr2 102630175 102630350 NM_001077514 Slc1a2 2.933
chr11 7072225 7072425 NM_009622 Adcy1 2.865
chr2 158211200 158211350 NM_175692 Snhg11 2.788
chr15 37326800 37327000 NM_134094 Ncald 2.685
chr2 102629600 102629788 NM_001077514 Slc1a2 2.672
chr15 37327000 37327200 NM_134094 Ncald 2.656
chr10 80644950 80645125 NM_007907 Eef2 2.451
chr2 102629788 102629975 NM_001077514 Slc1a2 2.392
chr11 59251613 59251750 NM_144521 Snap47 2.306
chr15 74581075 74581267 NM_011838 Lynx1 2.258
chr2 158211050 158211200 NM_175692 Snhg11 2.102
Shown are the top 20 genes that contain m6A peaks with the highest levels of enrichment.m6A peaks in the CDS and UTRs (Figure 5C). Although a
low percentage of m6A peaks was observed in intronic regions,
because our samples were not enriched for unspliced pre-
mRNAs, it is possible that additional methylated intronic
sequences exist.
We next sought to determine whetherm6A peaks are preferen-
tially found in certain portions of transcripts. To do this, we
assigned eachm6A peak to either a 50 UTR, CDS, or 30 UTR cate-
gory and assigned it to 1 of 100 bins based on its location along
the 50 UTR, CDS, or 30 UTR. These data show that m6A occurs
at low levels in the 50 UTR and in the 50 end of the CDS. In the
CDS, the percentage ofm6A peaks increases steadily along tran-
script length and is, on average, 5- to 6-fold higher at the end of
the CDS than at the beginning (Figure 5D). In the 30 UTR, the
peaks are enriched near the stop codon and decrease in
abundance along the length of the 30 UTR. Indeed, 61% of
m6A peaks are in the first quarter of the 30 UTR, and a quarter
of all m6A peaks across the entire transcriptome are found within
the first 26% of the 30 UTR (Figure 5D). Mapping the number of
m6A peaks 1 kb up- and downstream of CDS end sites further
demonstrated the high levels of methylation in the vicinity of
the stop codon (Figures S7A and S7B). Collectively, these data
indicate that m6A peaks are highly clustered in the vicinity of
the stop codon in mRNAs.
m6A Occurs in Highly Conserved Regions within Unique
Sequence Motifs
Wenext askedwhether m6A sites are conserved across species.
We compared PhyloP scores across 30 vertebrates (Pollardet al., 2010) of m6A peak regions to those of random regions of
the same size in gene exons. We found that the distribution of
conservation scores of the m6A peaks was significantly different
from that of the random regions (p% 2.2 3 1016, Kolmogorov-
Smirnov [K-S] test; Figure 6A) and that m6A peaks’ median
conservation score (0.578) was much higher than that of the
random regions (0.023). The fact that m6A frequently occurs in
evolutionarily conserved sequences suggests that m6A-contain-
ing regions are maintained through selection pressure.
Because the tools for transcriptome-wide localization of m6A
sites have until now been unavailable, only a few studies to
date have examined the sequence contexts of m6A formation
(Canaani et al., 1979; Dimock and Stoltzfus, 1977; Wei et al.,
1976). Using methods such as RNase T1 fingerprinting of radio-
labeled RNA followed by separation by thin-layer chromatog-
raphy, these studies reported that m6A exists within two unique
sequence contexts: GAC and AAC (underlined adenosines
indicate m6A). Subsequently, an extended m6A consensus
sequence was identified: PuPuACX (Pu = purine; X = A, C, or
U). However, because the methods used in these studies are
not practical for use in a high-throughput manner, it is unclear
whether these motifs are relevant to the transcriptome-wide
m6A sites identified by MeRIP-Seq.
We therefore sought to identify sequence motifs that are
enriched within m6A peaks. To do this, we used FIRE, a sensitive
and unbiased tool for discovering RNA regulatory elements
(Elemento et al., 2007). Remarkably, FIRE independently identi-
fied the GAC and AAC motif, G[AG]ACU, and related variants
([AC]GAC[GU], GGAC, [AU][CG]G[AG]AC, and UGAC) as beingCell 149, 1635–1646, June 22, 2012 ª2012 Elsevier Inc. 1641
Figure 6. MeRIP-Seq Reveals Features of m6A in mRNA
(A) Phylogenetic conservation of m6A peaks. PhyloP scores of m6A peak regions were compared to those of randomly shuffled regions throughout gene exons.
There was a significantly higher median conservation score (K-S test, *p% 2.2 3 10-16) in m6A peaks (0.578) than in the random regions (0.023).
(B) Sequence motifs identified within m6A peaks. The motif G[AG]ACU and variants thereof ([AC]GAC[GU], GGAC, [AU][CG]G[AG]AC, and UGAC) were highly
enriched inm6A peaks. Additionally, one U-richmotif (lower-right) was identified as being significantly underrepresentedwithinm6A peaks. Color bars under each
motif indicate the degree of underrepresentation (blue) or overrepresentation (yellow) within regions of m6A peaks in the non-IP control sample (CNTL) and the
MeRIP sample (MeRIP).
(C) m6A motif sequences frequently lie near the center of m6A peaks. Shown is a plot of the cumulative distribution of m6A motif positions within m6A peaks
containing a single motif. Motifs cluster in the center of peaks, suggesting that the methylated adenosines in these motifs account for the m6A peaks identified in
MeRIP-Seq.
(D) Example of a m6A motif sequence near the center of a peak. UCSC Genome Browser plot containing tracks for MeRIP-Seq reads (red) and non-IP control
reads (black) at the Ilf2 locus. The m6A peak within the Ilf2 30 UTR contains a single m6A motif identified in (B). The sequence of this motif (highlighted in yellow) is
located at the center of the m6A peak.
(E) Distribution of m6A peaks andmiRNA target sites within 30 UTRs. The frequency of m6A peaks (blue) andmiRNA target sites (red) along the length of 30 UTRs is
shown.
(F) Association between 30 UTRmethylation andmiRNA abundance. The 25most abundant miRNAs in brain have a significantly greater percentage of m6A peaks
within their target mRNA 30 UTRs than do the 25 most weakly expressed brain miRNAs (*p < 0.05, Wilcoxon test).
The error bars in (A) and (F) indicate the highest and lowest values, and the box boundaries denote the first quartile, median, and third quartile.
See also Figures S3, S6, and S7.
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highly enriched in m6A peaks (Figure 6B). For example, the
G[AG]ACU motif occurs in 42% of all m6A mRNA peaks and in
a much lower fraction (21%) of non-m6A control peaks from
the same mRNAs (p < 1.03 10124, chi-square test). Altogether,
we found that >90% of all m6A peaks contain at least one of the
motifs identified by FIRE.
We next examined the position of themotifs within m6A peaks.
Nearly 30% of m6A peaks have only one motif (Figure S6B), indi-
cating that these peaks are likely to contain only a single methyl-
ated residue. Motifs are also preferentially found in the center of
m6A peaks (Figures 6C and 6D), suggesting that these peaks
derive from a centrally located methylated adenosine residue.
Of note, other RNA regulatory elements, such as AU-rich
elements, poly(A) signals, or binding sites for known RNA-
binding proteins, were not identified by FIRE, suggesting that
m6A is unlikely to primarily function by modifying these known
regulatory elements.
Relationship between m6A Sites and Polyadenylation
Signals in 30 UTRs
FIRE did not identify an enrichment of poly(A) signals (PASs),
which are involved in 30 UTR end processing, in m6A peaks.
However, PASs exhibit considerable sequence heterogeneity
beyond the canonical AAUAAA consensus (Tian et al., 2005).
This sequence heterogeneity might allow these PASs to evade
detection by FIRE despite being enriched in m6A peaks.
Therefore, we sought to further investigate whether m6A peaks
within 30 UTRs are enriched at PASs. We obtained a high-confi-
dence list (Brockman et al., 2005) of poly(A) cleavage sites (the
site downstream of a PAS where the mRNA is actually cleaved
and polyadenylated) for the mRNAs that contain m6A peaks
within their 30 UTRs. We then examined whether m6A peaks
were enriched near these sites by determining the number of
30 UTR m6A peaks that fell within 50 nt upstream of each
cleavage site. Because a PAS is located 10–30 nt upstream
of an actual mRNA cleavage site (reviewed in Proudfoot, 1991),
these 50 nt long regions are expected to contain the PAS. Of
the 6,288 m6A peaks found within 30 UTRs, 1,042 (16.6%)
overlapped with the 50 nt long regions upstream of poly(A)
cleavage sites, compared to 1,070 (17.0%) control peaks, which
were generated from random nonoverlapping regions of the
same 30 UTRs. Thus, these data suggest that m6A does not
have a significant association with known PASs (p = 0.39;
chi-square test).
m6A Is Not Enriched at Splice Junctions
Prior studies that used nonspecific methylation inhibitors to
explore possible functions for m6A revealed impaired splicing
in a small number of RNAs (Carroll et al., 1990; Stoltzfus and
Dane, 1982). We therefore asked whether the localization
of m6A peaks is compatible with a role for influencing the binding
of splicing factors. However, only 80 splice junctions were found
in regions contiguous with m6A peaks, significantly fewer
than the overlap seen with a set of randomly generated peaks
(9,531; p = 0.0; chi-square test). Thus, unlike CLIP-Seq tag
clusters from RNA-binding proteins that influence splicing
(Licatalosi et al., 2008), m6A peaks did not significantly coincide
with exon-exon junctions, suggesting that m6A is unlikelyto primarily function to directly influence the binding of splicing
factors.
Relationship between m6A and MicroRNA-Binding Sites
within 30 UTRs
The strong enrichment of m6A peaks in 30 UTRs prompted
us to investigate whether m6A peaks are found near microRNA
(miRNA)-binding sites, which are also frequently observed within
30 UTRs. We found that 67% of 30 UTRs that contain m6A peaks
also contain at least one TargetScan-predicted miRNA-binding
site. Because 30% of genes have miRNA-binding sites in
their 30 UTRs (Lewis et al., 2005), this is a significantly greater
association than what would be expected by chance alone.
Intriguingly, we also found that, in 30 UTRs with both m6A peaks
and miRNA-binding sites, the m6A peaks precede miRNA-
binding sites 62% of the time. Moreover, we found that the
overall distribution of m6A peaks and miRNA-binding sites within
30 UTRs is anti-correlated; whereas m6A peaks are most
abundant near the stop codon and generally decrease in
frequency along 30 UTR length, miRNA target sites are more
enriched near the 30 end of 30 UTRs (Figure 6E). The reason for
this inverse localization pattern is unknown, though it could
indicate that a certain spatial separation is necessary for m6A
to influence the function of a downstream-bound miRNA or
vice versa.
We next sought to determine whether miRNA-targeted tran-
scripts in the brain are more likely to contain m6A. To test this,
we used TargetScan to identify the target transcripts of the 25
most highly expressed and 25 least highly expressed miRNAs
within the brain. Intriguingly, we observed that the most highly
expressed miRNAs have a significantly greater percentage of
target transcripts that contain m6A (p < 0.05, Wilcoxon test; Fig-
ure 6F). These data suggest that miRNA levelsmay control meth-
ylation of their target transcripts.
Prominent Features of m6A Distribution Are Conserved
in the Human Transcriptome
We next asked whether the enrichment of m6A in the 30 UTR
is also observed in other species. We therefore profiled m6A in
HEK293T cells, a human cell line with high levels of adenosine
methylation (Figure 3B). We generated a high-confidence list
of m6A peaks using three MeRIP-Seq biological replicates and
confirmed by both m6A antibodies. We found that the distribu-
tion of m6A peaks in HEK293T cells closely mirrored the distribu-
tion in mouse brain, with 31% and 53% of m6A peaks falling
within the 30 UTR and the CDS, respectively (Figures 5D and
S7D). As with the pattern of m6A distribution in the mouse brain
transcriptome, HEK293T m6A peaks were predominantly local-
ized near stop codons (Figures 5D and S7C).
In total, we identified 18,756 peaks in RNAs encoded by 5,768
genes in HEK293T cells (Table S6A). Additionally, we found that
transcripts from 2,145 and 3,259 genes were methylated only in
the mouse brain and HEK293T data sets, respectively, and that
transcripts from 2,509 genes were methylated in both data sets
(Table S6B). Interestingly, among the transcripts methylated in
both tissues,m6A peakswere often localized to the same distinct
regions of both orthologs (Figure 5E). Collectively, these data
indicate that m6A peaks are enriched near the stop codon inCell 149, 1635–1646, June 22, 2012 ª2012 Elsevier Inc. 1643
human transcripts and that many sites of methylation are
conserved in mouse and human transcripts.
DISCUSSION
Unlike DNA, which undergoes cytosine methylation and hydrox-
ymethylation, dynamic internal modifications of mRNA other
than RNA editing have not been established. Recent evidence
that the obesity risk gene, FTO, encodes a physiologic m6A
demethylase suggests that m6A has central roles in cellular func-
tion. Here, we useMeRIP-Seq to provide the first transcriptome-
wide characterization of m6A. We show that m6A is a reversible
and widespread modification that is primarily located in evolu-
tionarily conserved regions and is particularly enriched near
the stop codon. We also find that many features of m6A localiza-
tion are conserved between the human and mouse transcrip-
tomes, and we uncover a previously unidentified link between
m6A and miRNA signaling. Collectively, these studies reveal
that m6A is a widespread and dynamically regulated base modi-
fication in mRNA, and they identify mRNAs that are most likely to
be influenced by signaling pathways that influence m6A levels.
One of the most striking features of m6A localization is its
prevalence within 30 UTRs. The 30 UTR is an important region
for RNA regulation, as it can influence RNA stability, subcellular
localization, and translation regulation. Several of these events
are regulated by RNA-binding proteins (RBPs) that bind to
cis-acting structural motifs or consensus sequences within the
30 UTR and act to coordinate RNA processing. Conceivably,
m6A may influence the affinity of specific RBPs for their target
mRNAs, analogous to the recruitment of methyl-CpG-binding
protein 2 (MeCP2) tomethylated cytosine residues in DNA (Lewis
et al., 1992). Given the abundance of m6A throughout the
transcriptome and its widespread localization, such a role for
m6A would be likely to have important consequences for the
regulation of numerous mRNAs.
Our profiling of m6A in HEK293T cells revealed thousands
of transcripts that are also methylated in the mouse brain. In
many cases, the patterns of m6A localization within these
transcripts are nearly identical, suggesting that some RNAs
possess highly conserved methylation profiles. However, we
also uncovered many transcripts that exhibit distinct cell-type-
specific methylation patterns, demonstrating that m6A is also
capable of being differentially regulated within unique cellular
environments.
Our finding that a large proportion of 30 UTRs that contain m6A
peaks also contain miRNA binding sites is highly suggestive of
an association between m6A and miRNA function. Additionally,
our analysis indicated an inverse localization of m6A peaks and
miRNA-binding sites within 30 UTRs, with m6A sites typically
preceding, but not overlapping, the miRNA sites in the 30
UTRs. Although miRNAs can inhibit their target mRNAs by
promoting either transcript degradation or translational repres-
sion (Guo et al., 2010; Hendrickson et al., 2009), the factors
that determine which fate predominates are not well understood.
Conceivably, the proximity of m6A to amiRNA-binding site could
influence the mechanism of miRNA-mediated transcript inhibi-
tion. Additionally, it is possible that miRNA binding influences
m6A levels within 30 UTRs. Indeed, our finding that abundant1644 Cell 149, 1635–1646, June 22, 2012 ª2012 Elsevier Inc.miRNAs are more significantly enriched in m6A peaks than
weakly expressed miRNAs raises the possibility that miRNAs
regulate methylation status.
A surprising result of these studies is the finding that m6A is
highly enriched near stop codons. This recurrent localization
within transcripts suggests that adenosine methylation in the
vicinity of the stop codon may be of functional importance. Inter-
estingly, the consensus for adenosine methylation is relatively
short, and sequences that match the consensus are found
throughout the transcriptome. However, despite the frequency
of m6A consensus sites, methylation occurs primarily near stop
codons. It will be important to determine how this specificity is
achieved and whether cellular mechanisms that involve recogni-
tion of the stop codon or the beginning of the 30 UTR are involved
in providing specificity to adenosine methylation.
The finding that FTO demethylates m6A suggests that mis-
regulation of pathways controlled by adenosine methylation
ultimately affect physiologic processes in humans. Although
m6A is found in many classes of RNA, it is intriguing to speculate
that FTO mutations mediate their effects by affected m6A in
mRNA. Indeed, our finding that FTO can demethylate diverse
mRNAs is consistent with this model. Direct characterization of
m6Aprofiles inpatientswithFTOmutationswill beuseful to estab-
lish the mechanisms by which this mutation leads to disease.
In summary, our study demonstrates that m6A is a widespread
modification found in a large fraction of cellular mRNA. The
pervasive nature of this epitranscriptomic modification suggests
that adenosine methylation has important roles in RNA biology.
Much in the way that cytosine methylation and hydroxymethyla-
tion in DNA are important epigenetic regulators of the genome,
our data demonstrate that adenosine methylation in RNA is
a reversible modification throughout the transcriptome that is
likely to influence awide variety of biological pathways and phys-
iological processes.
EXPERIMENTAL PROCEDURES
MeRIP-Seq
Total mouse brain RNAwas subjected to RiboMinus treatment to reduce rRNA
content as per themanufacturer’s instructions (Invitrogen). RNAwas then frag-
mented to 100 nt sized fragments using Illumina Fragmentation Buffer accord-
ing to the manufacturer’s instructions and was subjected to two rounds of m6A
immunoprecipitation. Sequencing libraries were prepared using the Illumina
protocol for mRNA samples, and sequencing was performed on an Illumina
GAII3 or an Illumina HiSeq2000 as indicated. Genomic alignment (mm9 or
hg19 from UCSC genome browser) was done using the Burrows-Wheeler
Aligner (BWA) (Li and Durbin, 2010) at default settings, or using TopHat (see
Extended Experimental Procedures). We analyzed only those reads that (1)
uniquely mapped to the genome and (2) had a Phred quality scoreR20.
Additional methods are detailed in the Extended Experimental Procedures.
ACCESSION NUMBERS
MeRIP-Seq data have been deposited in the GEO database under accession
number GSE29714.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and six tables and can be found with this article online at doi:10.1016/
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